View Filing Data

Computers equipment [Member] | Top of range [Member]

3 years

Disclosure of detailed information about property, plant and equipment [line items]

Office furniture [Member]

5 years

Disclosure of detailed information about property, plant and equipment [line items]

Lab equipment [Member] | Bottom of range [Member]

5 years

Disclosure of detailed information about property, plant and equipment [line items]

Lab equipment [Member] | Top of range [Member]

7 years

Disclosure of detailed information about property, plant and equipment [line items]

Leasehold improvements [Member] | Bottom of range [Member]

10 years

Disclosure of detailed information about property, plant and equipment [line items]

Leasehold improvements [Member] | Top of range [Member]

3 years

^[1]

Disclosure of detailed information about property, plant and equipment [line items]

Disclosure of detailed information about financial instruments [line items]

5 years

^[1]

[1]	Leasehold improvements are depreciated over the lease period or the expected useful life of the improvements, whichever is shorter.

FINANCIAL INSTRUMENTS (Schedule of Classification of Financial Instruments by Groups - Liabilities) (Details) - USD ($)
$ in Thousands

Dec. 31, 2019

Dec. 31, 2018

Trade and other payable

$ 1,704

$ 1,563

Warrants to purchase ordinary shares (Level 1)

^[1]

266

1,372

Warrants to purchase ordinary shares (Level 3)

^[2]

2,178

Financial liabilities

4,148

2,935

Financial liabilities at fair value through profit or loss [Member]

Disclosure of detailed information about financial instruments [line items]

Trade and other payable

Warrants to purchase ordinary shares (Level 1)

^[1]

266

1,372

Warrants to purchase ordinary shares (Level 3)

^[2]

2,178

Financial liabilities

2,444

1,372

Financial liabilities at amortized cost [Member]

Disclosure of detailed information about financial instruments [line items]

Trade and other payable

1,704

1,563

Financial liabilities

$ 1,704

$ 1,563

[1]	Tradable warrants presented above are valuated based on the market price (a Level 1 valuation) as of December 31, 2019.
[2]	Warrants to purchase ordinary shares issued in December 2019 presented are valuated based on the Monte-Carlo pricing model (a Level 3 valuation) as of December 31, 2019.

- Definition

The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity’s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity’s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]

+ References + Details

FINANCIAL INSTRUMENTS (Schedule of Assumptions) (Details) - Financial Instruments [Member]	12 Months Ended
	Dec. 31, 2019 $ / shares
Disclosure of detailed information about financial instruments [line items]
Expected term	3 years
Expected dividend	0.00%
Bottom of range [Member]
Disclosure of detailed information about financial instruments [line items]
Price per share	$ 1.84
Volatility	62.00%
Risk free interest rate	1.63%
Top of range [Member]
Disclosure of detailed information about financial instruments [line items]
Price per share	$ 2.07
Volatility	63.00%
Risk free interest rate	1.71%

CASH AND CASH EQUIVALENTS (Schedule of Cash and Cash Equivalents) (Details) - USD ($)
$ in Thousands

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Cash and cash equivalents [abstract]

Cash in bank

$ 15,185

$ 5,499

Short-term bank deposits

^[1]

2,007

Cash and cash equivalents

$ 15,185

$ 7,506

$ 11,746

$ 4,163

Interest rate on deposits

2.17%

[1]	The short-term bank deposit as of December 31, 2018 was in U.S. dollar and bear an annual interest rate of 2.17%.

INTANGIBLE ASSETS (Details) - USD ($)	Jun. 01, 2010	Feb. 22, 2011
D.N.A. and Oramed [Member]
Disclosure of detailed information about intangible assets [line items]
Percentage of ordinary shares	50.00%
D.N.A. Biomedical Solutions Ltd. [Member]
Disclosure of detailed information about intangible assets [line items]
Amount invested in joint venture	$ 600,000
Oramed [Member]
Disclosure of detailed information about intangible assets [line items]
Percentage of royalties to be paid		3.00%

CONVERTIBLE LOANS (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended			12 Months Ended
	Aug. 05, 2015	Oct. 31, 2017	Jun. 30, 2016	Oct. 31, 2015	Dec. 31, 2018	Dec. 31, 2012	Dec. 31, 2019	Jun. 14, 2016
Disclosure of detailed information about borrowings [line items]
Interest rate							16.00%
Conversion of convertible loan into Ordinary shares					$ 4,138
2012 Convertible Loan [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings						$ 1,200
Interest rate						0.60%
Maturity						Each of the loans bears interest at a rate of 0.6% per year, which is to be repaid every five years, the loan is due and payable after a term of twenty years.
Conversion price per share						$ 240.26
Convertible loan converted into ordinary shares					622,180	622,180
Conversion of convertible loan into Ordinary shares						$ 4,100
2012 Convertible Loan [Member] \| D.N.A [Member]
Disclosure of detailed information about borrowings [line items]
Number of ordinary shares exchanged						5,590
Number of stock merged				2,795
2015 Convertible Loan [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 1,100
Interest rate	5.00%
Maturity	February 2017
Discount to the applicable price per share in the triggering event	25.00%
Percentage of warrants to purchase additional shares on conversion	40.00%
Finance expenses	$ 64
Converted to 2016 Loans [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 2,000		$ 1,100
Deposit amount at trustee								$ 1,100
2016 Convertible Loan [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings			$ 7,400					$ 1,000
Interest rate			5.00%
Maturity			18 months
Conversion price per share		$ 5.24
Description of automatically converted loan to shares			The loan will be automatically converted upon occurrence of the following events as described in the agreement: IPO of at least $20 million, private placement in an aggregate amount of no less than $10 million or change of control (the "Triggering Event"). Furthermore, in case of private placement in an aggregate amount of $4-$10 million the lenders shall have the right to convert the loan to shares. The loan will convert into the same class of shares issued in such a transaction at the lower of a 25% discount to the applicable price per share in the Triggering Event or the value of equity on a fully diluted basis of $65 million.
Exercisable period of warrants			4 years
Convertible loan and accrued interest converted into series B-1 preferred shares			1,719,770
Exercise price of warrants		$ 6.99
Percentage of warrants to purchase additional shares on conversion			40.00%

CONVERTIBLE LOANS (Schedule of Convertible Components) (Details) - Convertible loans [Member]

Jul. 02, 2018

$ / shares

Disclosure of detailed information about borrowings [line items]

Price per share

$ 865

^[1]

Volatility

62.00%

Probability of entering Phase 2b/3

Probability for IPO

100.00%

[1]	The price per share as of July 2, 2018 was based on quoted price on Nasdaq before the shares split.

PREFERRED SHARES AND WARRANTS TO PREFERED SHARES (Narrative) (Details)
$ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

12 Months Ended

Oct. 04, 2019

USD ($)

$ / shares

Jul. 02, 2018

$ / shares

Jan. 11, 2015

USD ($)

Jul. 31, 2019

USD ($)

Jul. 20, 2019

USD ($)

$ / shares

Oct. 31, 2017

$ / shares

Jan. 29, 2015

USD ($)

Dec. 29, 2014

USD ($)

Dec. 31, 2017

USD ($)

$ / shares

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Disclosure of classes of share capital [line items]

Effective price per share | $ / shares

1,177,131

143,000

1,944,670

$ 3.69

Reclassification from other reserves to additional paid in capital | $

$ 1,400

2016 Convertible Loan [Member]

^[1]

662,251

31,460

Disclosure of classes of share capital [line items]

Additional Centillion preferred share purchase agreement [Member]

$ 6.99

Disclosure of classes of share capital [line items]

5,111

2,555

$ 2,500

$ 1,300

Second amendment to Centillion preferred share purchase agreement [Member]

1,277

639

Disclosure of classes of share capital [line items]

Percentage of discount applicable to price per share

$ 2,500

25.00%

Preferred Shares Series B- 1 [Member]

Disclosure of classes of share capital [line items]

Number of warrants converted into additional warrants to purchase ordinary shares

467,220

3,594

Preferred Shares Series B- 1 [Member] | 2016 Convertible Loan [Member]

$ 681.585

Disclosure of classes of share capital [line items]

Shares issued in conversion of debt

13,229

Shares issued in conversion of debt, value | $

$ 9,000

Shares issued in conversion of debt, price per share | $ / shares

$ 681.585

Preferred Shares Series B- 1 [Member] | 2016 Convertible Loan [Member] | Related parties [member]

Disclosure of classes of share capital [line items]

Number of preferred shares purchased after share split

1,834

238,420

Warrants issued to purchase shares after share split

733

95,290

Fair value of preferred shares | $

$ 1,600

Fair value of warrants | $

$ 264

Series A preferred shares [Member]

Disclosure of classes of share capital [line items]

Number of warrants converted into additional warrants to purchase ordinary shares

332,020

2,554

Number of preferred shares converted to ordinary shares following closing of IPO

10,222

Series A preferred shares [Member] | Investors [Member]

1,328,860

Disclosure of classes of share capital [line items]

Series B preferred shares [Member]

387,530

Disclosure of classes of share capital [line items]

7,089

$ 6,400

$ 908.78

Series B preferred shares [Member] | Investors [Member]

1,856,790

Disclosure of classes of share capital [line items]

Preferred shares, price per share | $ / shares

$ 13,000

$ 908.78

Total consideration net of issuance costs | $

14,283

$ 12,100

Series B preferred shares [Member] | Broker dealer [Member]

Disclosure of classes of share capital [line items]

Preferred shares, price per share | $ / shares

$ 908.78

Additional issuance costs | $

526

$ 198

Shareholders exercised his right to acquire ordinary shares [Member]

Disclosure of classes of share capital [line items]

Value of options exercised | $

32,500

$ 100

Warrants [Member]

Disclosure of classes of share capital [line items]

$ 8.4

Exceeds sales price per share | $ / shares

443,950

Warrant term

five years

$ 24.00

Percentage of per unit price

300.00%

Warrants [Member] | 2016 Convertible Loan [Member]

Disclosure of classes of share capital [line items]

Effective price per share | $ / shares

467,220

$ 5.24

Reclassification from other reserves to additional paid in capital | $

$ 1,200

Centillion preferred share purchase agreement [Member]

Disclosure of classes of share capital [line items]

5,111

$ 2,500

Disclosure of fair value measurement of assets [line items]

1,277

[1]	The total intrinsic value of options exercised during the year ended December 31, 2019, was approximately $2,391 thousand.

PREFERRED SHARES AND WARRANTS TO PREFERED SHARE (Schedule of Valuations of Fair Value of Instruments) (Details) - Level 3 [Member]

Jul. 02, 2018

$ / shares

Price per share

$ 865

^[1]

Volatility

62.00%

Probability of entering Phase 2b/3

Probability for IPO

100.00%

[1]	The price per share as of July 2, 2018 was based on quoted price on Nasdaq before shares split.

COMMITMENTS (Details) - USD ($) $ in Thousands		12 Months Ended
COMMITMENTS (Details) - USD ($) $ in Thousands	Feb. 10, 2019	Dec. 31, 2019
Statement Line Items [Line Items]
Percentage of royalty payable on sales of products developed during first three years		3.00%
Percentage of royalty payable on sales of products developed during subsequent three years		4.00%
Percentage of royalty payable on sales of products developed during commencing of seventh year		5.00%
Percentage of royalty payable on grants received by company		100.00%
Royalty amount payable		$ 460
Percentage to be paid for each payment received		5.38%
Amgen Inc [Member]
Statement Line Items [Line Items]
Amount paid to government of israel	$ 27

LEASES (Narrative) (Details)	12 Months Ended
LEASES (Narrative) (Details)	Dec. 31, 2019 USD ($)
Disclosure of quantitative information about right-of-use assets [line items]
Bank guarantees	$ 30,000
Borrowings rate	16.00%
Buildings [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Annual lease consideration total amount	$ 164,000
Lease expiration date	Jun. 30, 2023

LEASES (Schedule of Composition of Right-of-Use Assets) (Details) $ in Thousands	Dec. 31, 2019 USD ($)
Disclosure of quantitative information about right-of-use assets [line items]
Total right-of-use asset	$ 260
Initial Application of IFRS 16 [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Total right-of-use asset	166
Facility [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Total right-of-use asset	253
Facility [Member] \| Initial Application of IFRS 16 [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Total right-of-use asset	151
Vehicles [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Total right-of-use asset	7
Vehicles [Member] \| Initial Application of IFRS 16 [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Total right-of-use asset	$ 15

LEASES (Schedule of Summarize Contractual Obligations) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Disclosure of maturity analysis of operating lease payments [line items]
Operating leases for facility and vehicles	$ 346	$ 123
Less than 1 year [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Operating leases for facility and vehicles	177	87
1-3 years [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Operating leases for facility and vehicles	$ 169	$ 36

LEASES (Schedule of Leases) (Details) $ in Thousands	12 Months Ended
LEASES (Schedule of Leases) (Details) $ in Thousands	Dec. 31, 2019 USD ($)
Disclosure of quantitative information about right-of-use assets [line items]
Financial expense	$ 55
Cash paid for amounts included in the measurement of lease liabilities	169
Right of use assets obtained in exchange for new operating lease liabilities	224
Facility [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Depreciation expense:	121
Vehicles [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Depreciation expense:	$ 9

SHARE CAPITAL (Narrative) (Details)

1 Months Ended

3 Months Ended

12 Months Ended

Dec. 13, 2019

USD ($)

$ / shares

Aug. 05, 2019

USD ($)

$ / shares

Jul. 02, 2018

USD ($)

$ / shares

Jan. 10, 2018

USD ($)

$ / shares

Feb. 18, 2020

USD ($)

Dec. 31, 2019

USD ($)

$ / shares

Nov. 30, 2019

USD ($)

$ / shares

Nov. 18, 2019

USD ($)

$ / shares

Jul. 20, 2019

Jan. 17, 2019

USD ($)

$ / shares

Jul. 26, 2018

USD ($)

Jan. 30, 2018

USD ($)

$ / shares

Dec. 31, 2017

$ / shares

Dec. 31, 2019

USD ($)

$ / shares

Dec. 31, 2018

USD ($)

$ / shares

Dec. 31, 2017

USD ($)

$ / shares

Dec. 31, 2012

Jan. 22, 2020

Dec. 31, 2019

₪ / shares

Dec. 31, 2018

₪ / shares

Mar. 17, 2013

$ / shares

Disclosure of classes of share capital [line items]

Stock split

1-for- 130

Proceeds from issuance of ordinary shares, net | $

17,864,684

11,459,780

$ 12,528,000

Ordinary shares remain available for future grants

204,263

Percentage of aggregate purchase price paid in cash by purchasers equal to per month

$ 12,087,000

1.00%

Par value per share | (per share)

₪ 0.0000769

$ 0.0000769

1,177,131

143,000

1,944,670

Remaining unrecognized compensation expense | $

$ 3.12

$ 5.35

$ 6.39

$ 1,900,000

Transaction costs | $

$ 1,200,000

Capital stock price per share | $ / shares

$ 2.37

Reserved ordinary shares

1,371,398

Under Company Plan [Member]

^[1]

662,251

31,460

Disclosure of classes of share capital [line items]

Increase of ordinary shares remain available for future grants

893,234

D.N.A. Placement [Member]

Disclosure of classes of share capital [line items]

337,553

Warrants granted to purchase ordinary shares

$ 800,000

168,776

$ 2.96

Disclosure of classes of share capital [line items]

Exercisable over a three-year period from the date of issuance

Dr. Eric Lang [Member]

110,500

$ 6.31

The options vest over 4 years from the date of grant; 1/4 vest on the date of grant and the remaining vest in twelve equal quarterly installments following the first anniversary of the applicable grant date.

2012 Convertible Loan [Member]

$ 420,000

Disclosure of classes of share capital [line items]

Convertible loan converted into ordinary shares

622,180

IPO [Member]

Disclosure of classes of share capital [line items]

IPO [Member] | Underwriters [Member]

1,400,000

Disclosure of classes of share capital [line items]

Warrants issued to purchase shares

10,000

70,000

Stock issuance costs | $

$ 255,000

Fair value of warrants | $

$ 8.8

$ 66,500

Warrants [Member]

Disclosure of classes of share capital [line items]

1,400,000

Adjusted exercise price of warrants | $ / shares

$ 8.4

Warrant term

five years

$ 5.85

Exceeds sales price per share | $ / shares

$ 24.00

Percentage of per unit price

300.00%

Warrants [Member] | Underwriters [Member]

443,950

Disclosure of classes of share capital [line items]

Warrants converted into ordinary shares

105,000

Proceeds from issuance of ordinary shares, net | $

$ 2,100

Warrants granted to purchase ordinary shares

210,000

Fair value of warrants | $

$ 172,000

Ordinary shares [member]

Disclosure of classes of share capital [line items]

Warrants issued to purchase shares

700,000

Proceeds from issuance of ordinary shares, net | $

$ 9,600,000

Proceeds from issuance of ordinary shares, gross | $

11,200,000

Underwriters fee | $

900,000

Other issuance costs | $

$ 700,000

Public offering price per unit | $ / shares

$ 8.0

Number of ordinary shares that can be purchased through each tradeable warrant

0.5

Series A preferred shares [Member]

Disclosure of classes of share capital [line items]

Series A preferred shares [Member] | Investors [Member]

1,328,860

Disclosure of classes of share capital [line items]

Series B preferred shares [Member]

387,530

Disclosure of classes of share capital [line items]

$ 908.78

Series B-1 preferred shares [Member]

1,856,790

Disclosure of classes of share capital [line items]

Warrants to series A preferred shares [Member]

1,719,770

Disclosure of classes of share capital [line items]

Warrants to series A preferred shares [Member] | Investors [Member]

343,200

Disclosure of classes of share capital [line items]

Warrants to series B preferred shares [Member]

85,931

Disclosure of classes of share capital [line items]

Warrants to series B-1 preferred shares [Member]

756,340

Disclosure of classes of share capital [line items]

Broker Warrants type 1 [Member]

467,220

Disclosure of classes of share capital [line items]

Broker Warrants type 2 [Member]

184,515

Disclosure of classes of share capital [line items]

Share-based Compensation Expense [member]

92,257

Disclosure of classes of share capital [line items]

Transaction costs | $

$ 205,000

Certain Consultant [Member]

Disclosure of classes of share capital [line items]

32,500

$ 2.11

The options vested immediately.

Options granted to services providers [Member]

$ 138,000

Disclosure of classes of share capital [line items]

65,693

$ 3.10

The options will vest over six months in in six equal monthly instalments starting in August 2019.

New US-based CFO [Member]

$ 90,000

Disclosure of classes of share capital [line items]

30,385

$ 2.53

The options will vest over two years in equal monthly installments following the grant date.

Non-executive director [Member]

$ 37,000

Disclosure of classes of share capital [line items]

33,638

201,828

$ 2.53

$ 3.97

The options will vest over 3 years in twelve equal quarterly instalments starting on the vesting commencement date (as described in the agreement).

The options will vest over 3 years in twelve equal quarterly instalments starting in the vesting commencement date (as described in each agreement).

Certain employees [Member]

$ 43,000

$ 531,000

Disclosure of classes of share capital [line items]

124,000

$ 3.97

The options vest over 4 years from the date of grant; 25% will vest on the first anniversary of the date of grant and the remaining 75% options shall vest in twelve equal quarterly installments following the first anniversary of the grant date.

Disclosure of classes of share capital [line items]

$ 341,000

CMO [Member]

25,000

$ 3.97

From the total options, 25% will vest on March 1, 2019 and the remaining 75% options shall vest in twelve equal quarterly installments over the next three years starting January 17,2019.

Disclosure of classes of share capital [line items]

$ 68,000

New CEO [Member]

696,587

$ 2.75

The options vest over 4 years from the date of grant. 25% will vest on the first anniversary of the date of grant and the remaining 75% options shall vest in twelve equal quarterly installments following the first anniversary of the grant date.

Placement Agency agreement with GP Numenkari Inc [Member]

$ 1,100,000

Disclosure of classes of share capital [line items]

Percentage of cash fees of total proceeds

10.00%

Percentage of number of shares issued to subscribers

10.00%

Placement Agency agreement with GP Numenkari Inc [Member] | Broker Warrants type 1 [Member]

Disclosure of classes of share capital [line items]

Percentage of number of shares issued to subscribers

10.00%

Placement Agency agreement with GP Numenkari Inc [Member] | Broker Warrants type 2 [Member]

$ 2.37

Disclosure of classes of share capital [line items]

Percentage of number of shares issued to subscribers

5.00%

Executive officers and former Executive officer [Member]

$ 2.96

Disclosure of classes of share capital [line items]

Number of options exrercised to ordinary shares

662,251

662,251

Value of options exercised | $

$ 138,000

Subscription agreements with select group of accredited investors for private placement [Member]

Disclosure of classes of share capital [line items]

5,710,153

Share issue price per share | $ / shares

$ 13,500,000

$ 2.37

Warrants granted to purchase ordinary shares

2,855,095

2,855,095

$ 2.96

Outstanding at beginning of year | shares

Exercisable over a three-years period from the date of issuance.

[1]	The total intrinsic value of options exercised during the year ended December 31, 2019, was approximately $2,391 thousand.

SHARE CAPITAL (Schedule of Composed of Ordinary Shares) (Details)	Dec. 31, 2019 ₪ / shares shares	Dec. 31, 2018 ₪ / shares shares	Mar. 17, 2013 $ / shares
Disclosure of classes of share capital [abstract]
Authorized	140,010,000	140,010,000
Issued	17,864,684	11,459,780
Par value per share \| (per share)	₪ 0.0000769	₪ 0.0000769	$ 0.0000769

SHARE CAPITAL (Schedule of Weighted Average Assumptions) (Details)	12 Months Ended
	Dec. 31, 2019 Years $ / shares	Dec. 31, 2018 Years $ / shares	Dec. 31, 2017 Years $ / shares
Disclosure of classes of share capital [abstract]
Ordinary share price	$ 2.94	$ 6.31	$ 5.95
Exercise price	$ 3.12	$ 5.35	$ 5.95
Dividend yield
Expected volatility	71.00%	68.00%	73.77%
Risk-free interest rate	1.86%	2.23%	1.67%
Expected life - in years \| Years	9.37	4.07	7.94

SHARE CAPITAL (Schedule of Changes in Number of Options and Weighted Average Exercise Prices) (Details)
$ / shares in Units, $ in Thousands

12 Months Ended

Dec. 31, 2019

USD ($)

$ / shares

Dec. 31, 2018

$ / shares

Dec. 31, 2017

$ / shares

Number of options

2,438,410

3,044,990

1,136,590

Expired | shares

(91,000)

Forfeited | shares

(14,690)

(718,120)

(36,270)

Exercised | shares

^[1]

(662,251)

(31,460)

Granted | shares

1,177,131

143,000

1,944,670

Outstanding at end of year | shares

2,847,600

2,438,410

3,044,990

Exercisable at end of year | shares

1,525,618

1,837,160

1,430,780

Weighted average exercise price

Outstanding at beginning of year | $ / shares

$ 4.36

$ 4.59

$ 1.43

Expired | $ / shares

6.31

Forfeited | $ / shares

4.44

5.73

2.27

Exercised | $ / shares

^[1]

0.21

Granted | $ / shares

3.12

5.35

6.39

Outstanding at end of year | $ / shares

4.74

4.36

4.59

Exercisable at end of year | $ / shares

$ 5.62

$ 1.67

$ 2.92

Intrinsic value | $

$ 2,391

[1]	The total intrinsic value of options exercised during the year ended December 31, 2019, was approximately $2,391 thousand.

SHARE CAPITAL (Schedule of Information about Exercise Price and Remaining Contractual Life of Outstanding Options) (Details)

12 Months Ended

Dec. 31, 2019

$ / shares

Dec. 31, 2018

$ / shares

Dec. 31, 2017

Dec. 31, 2016

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

Exercise Price One [Member]

2,847,600

2,438,410

3,044,990

1,136,590

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

4,680

602,810

^[1]

Exercise Price Two [Member]

2 years 9 months 14 days

6 months 18 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

11,050

27,560

$ 1.85

Exercise Price Three [Member]

1 year 2 months 19 days

8 months 2 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

36,010

$ 2.43

Exercise Price Four [Member]

0 years

1 year 4 months 28 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

65,000

$ 2.11

Exercise Price Five [Member]

18 days

1 year 18 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

64,023

$ 2.53

Exercise Price Six [Member]

9 years 10 months 21 days

0 years

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

696,587

$ 2.75

Exercise Price Seven [Member]

9 years 7 months 6 days

0 years

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

11,050

$ 1.85

Exercise Price Eight [Member]

0 years

2 years 2 months 16 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

65,693

$ 3.10

Exercise Price Nine [Member]

4 years 10 months 21 days

0 years

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

203,970

205,920

$ 3.69

Exercise Price Ten [Member]

2 years 4 months 9 days

3 years 4 months 9 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

340,828

$ 3.97

Exercise Price Eleven [Member]

9 years 18 days

0 years

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

1,248,479

1,342,770

$ 6.31

Exercise Price Twelve [Member]

5 years 10 months 6 days

6 years 4 months 20 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

147,290

$ 7.54

Basic and diluted earnings per share [abstract]

3 years 3 months 4 days

4 years 3 months 4 days

[1]

Par value

TAXES ON INCOME (Details) - USD ($) $ in Millions	12 Months Ended
TAXES ON INCOME (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Major components of tax expense (income) [abstract]
Israel corporate tax rates	23.00%	23.00%	24.00%
Carryforward losses	$ 31.0	$ 21.0
Income tax rate in United states	21.00%

REVENUE FROM COLLABORATION AND LICENSE AGREEMENT (Narrative) (Details) - USD ($) $ in Thousands		1 Months Ended		12 Months Ended
	Dec. 10, 2018	Jan. 31, 2020	Jan. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contract with customer				$ 236	$ 500
Amgen Inc [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Amount to be paid for preclinical services		$ 225
Amgen Inc [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues generated from research collaboration and license agreement	$ 270,000
Non-refundable and non-creditable initial technology access fee payment			$ 725
Amount to be paid for preclinical services	$ 450
Contract Liabilities				267	$ 225
Additional amount paid for services to be recognized upon commencement of the pre-clinical Research and Development services				225
Revenue from contract with customer				500
Amount of performance obligations				$ 500

SUPPLEMENTARY FINANCIAL INFORMATION (Schedule of Other Current Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Other current assets:
Prepaid expenses	$ 39	$ 109
Restricted deposits	37	21
Other	97	90
Other current assets	$ 173	$ 220

SUPPLEMENTARY FINANCIAL INFORMATION (Schedule of Accounts Payable Other) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accounts payable - other:
Employees and employees related	$ 345	$ 120
Provision for vacation	231	215
Accrued expenses and other	794	755
Accounts payable - other	$ 1,370	$ 1,090

BASIC AND DILUTED LOSS PER SHARE (Narrative) (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Warrants [Member]
Disclosure of classes of share capital [line items]
Number of ordinary shares related to the outstanding options excluded from the calculation of diluted loss per share	4,849,855
2012 Convertible Loan, 2016 Convertible Loan, preferred shares and warrants [Member]
Disclosure of classes of share capital [line items]
Number of ordinary shares related to the outstanding options excluded from the calculation of diluted loss per share		10,596,130	7,687,030

BASIC AND DILUTED LOSS PER SHARE (Schedule of Basic and Diluted Loss Per Share) (Details) - USD ($)
$ / shares in Units, $ in Thousands

12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Loss attributable to equity holders of the Company

$ 10,795

$ 10,304

$ 11,197

Income from change in fair value of financial liabilities at fair value

135

Loss used for the computation of diluted loss per share

$ 10,795

$ 10,439

$ 11,197

Weighted average number of ordinary shares used in the computation of basic loss per share

^[1]

12,146,729

7,955,447

4,490,720

Add: Weighted average number of additional shares issuable upon the assumed conversion/exercise of preferred shares and warrants to issue preferred shares and shares

27,955

Weighted average number of ordinary shares used in the computation of diluted loss per share

^[1]

12,146,729

7,983,402

4,490,720

Basic loss per ordinary share

^[1]

$ 0.89

$ 1.30

$ 2.49

Diluted loss per ordinary share

^[1]

$ 0.89

$ 1.31

$ 2.49

[1]	Retroactively adjusted due to ordinary shares split, see note 11.

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

RELATED PARTIES - TRANSACTIONS AND BALANCES (Schedule of Transactions with Related Parties) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Key management compensation:
Labor cost and related expenses	$ 1,537	$ 1,180	$ 1,048
Share-based compensation	1,146	868	4,694
Directors fee and services	415	429	577
Others	23	30	109
Key management compensation	$ 3,121	$ 2,507	$ 6,428

RELATED PARTIES - TRANSACTIONS AND BALANCES (Schedule of Balances with Related Parties) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Key management:
Payables and accrued expenses	$ 244	$ 9
Severance pay obligations	70	65
Provision for vacation	194	186
Directors fee and services	$ 106	$ 74

SUBSEQUENT EVENTS (Details)

1 Months Ended

12 Months Ended

Dec. 13, 2019

USD ($)

$ / shares

Mar. 16, 2020

$ / shares

Feb. 18, 2020

USD ($)

Jan. 31, 2020

USD ($)

Dec. 31, 2019

USD ($)

$ / shares

Dec. 31, 2018

USD ($)

$ / shares

Dec. 31, 2017

USD ($)

$ / shares

Disclosure of non-adjusting events after reporting period [line items]

^[1]

662,251

31,460

$ 12,087,000

1,177,131

143,000

1,944,670

Disclosure of non-adjusting events after reporting period [line items]

$ 3.12

$ 5.35

$ 6.39

Consultant [Member]

Number of options exercised to ordinary shares

32,500

32,500

Value of options exercised | $

$ 69,000

D.N.A. Placement [Member]

Disclosure of non-adjusting events after reporting period [line items]

$ 800,000

$ 2.96

Certain Employees [Member]

Exercisable over a three-year period from the date of issuance

Disclosure of non-adjusting events after reporting period [line items]

201,600

$ 2.14

Certain Service Providers [Member]

The options vest over 4 years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% vest in twelve equal quarterly installments following the first anniversary of the applicable grant date.

Disclosure of non-adjusting events after reporting period [line items]

7,500

$ 2.14

Certain Executive Officers [Member]

Disclosure of non-adjusting events after reporting period [line items]

250,000

$ 2.14